Skip to main navigation Skip to search Skip to main content

Podocyte number and glomerulosclerosis indices are associated with the response to therapy for primary focal segmental glomerulosclerosis

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Corticosteroid therapy, often in combination with inhibition of the renin-angiotensin system, is first-line therapy for primary focal and segmental glomerulosclerosis (FSGS) with nephrotic-range proteinuria. However, the response to treatment is variable, and therefore new approaches to indicate the response to therapy are required. Podocyte depletion is a hallmark of early FSGS, and here we investigated whether podocyte number, density and/or size in diagnostic biopsies and/or the degree of glomerulosclerosis could indicate the clinical response to first-line therapy. In this retrospective single center cohort study, 19 participants (13 responders, 6 non-responders) were included. Biopsies obtained at diagnosis were prepared for analysis of podocyte number, density and size using design-based stereology. Renal function and proteinuria were assessed 6 months after therapy commenced. Responders and non-responders had similar levels of proteinuria at the time of biopsy and similar kidney function. Patients who did not respond to treatment at 6 months had a significantly higher percentage of glomeruli with global sclerosis than responders (p < 0.05) and glomerulosclerotic index (p < 0.05). Podocyte number per glomerulus in responders was 279 (203–507; median, IQR), 50% greater than that of non-responders (186, 118–310; p < 0.05). These findings suggest that primary FSGS patients with higher podocyte number per glomerulus and less advanced glomerulosclerosis are more likely to respond to first-line therapy at 6 months. A podocyte number less than approximately 216 per glomerulus, a GSI greater than 1 and percentage global sclerosis greater than approximately 20% are associated with a lack of response to therapy. Larger, prospective studies are warranted to confirm whether these parameters may help inform therapeutic decision making at the time of diagnosis of primary FSGS.

Original languageEnglish
Article number1343161
Number of pages14
JournalFrontiers in Medicine
Volume11
DOIs
Publication statusPublished - 2024

Keywords

  • FSGS
  • kidney
  • podocyte
  • podometrics
  • therapy
  • ARC Training Centre for Cell and Tissue Engineering Technologies

    Meagher, L. (Primary Chief Investigator (PCI)), Bray, L. J. (Chief Investigator (CI)), Voelcker, N. (Chief Investigator (CI)), Risbridger, G. (Chief Investigator (CI)), Hutmacher, D. W. (Chief Investigator (CI)), Batra, J. (Chief Investigator (CI)), Dargaville, T. (Chief Investigator (CI)), Elnathan, R. (Chief Investigator (CI)), Saifzadeh, S. (Chief Investigator (CI)), Heng, T. (Chief Investigator (CI)), Aguilar, M. (Chief Investigator (CI)), Lim, R. (Partner Investigator (PI)), Klein, T. J. (Chief Investigator (CI)), Fisher, A. (Partner Investigator (PI)), McGovern, J. (Chief Investigator (CI)), Dislakis, V. (Partner Investigator (PI)), McLellan, A. (Partner Investigator (PI)), Dulleck, U. (Chief Investigator (CI)), Steck, R. (Chief Investigator (CI)), Scott, W. (Partner Investigator (PI)), Corrie, S. (Chief Investigator (CI)), Thissen, H. (Partner Investigator (PI)), Cameron, N. (Chief Investigator (CI)), Haupt, L. (Chief Investigator (CI)), Werner, C. (Partner Investigator (PI)), Levett, P. (Partner Investigator (PI)), Whyte, S. (Chief Investigator (CI)), Forsythe, J. (Chief Investigator (CI)), Smith, N. (Partner Investigator (PI)), Frith, J. (Chief Investigator (CI)), Hicks, C. (Partner Investigator (PI)), Rackham, O. J. L. (Partner Investigator (PI)), Sohal, A. (Chief Investigator (CI)), Polo, J. (Chief Investigator (CI)), May, M. (Partner Investigator (PI)), Reimers, N. (Partner Investigator (PI)), Toh, Y.-C. (Chief Investigator (CI)), McKee, J. (Partner Investigator (PI)), Adams, M. (Chief Investigator (CI)), Obschonka, M. (Partner Investigator (PI)), Subramaniam, N. (Chief Investigator (CI)), Yambem, S. D. (Chief Investigator (CI)), Russell-Bennett, R. (Chief Investigator (CI)), Bertram, J. (Chief Investigator (CI)), Schierjott, R. (Partner Investigator (PI)), Hollands, J. (Partner Investigator (PI)), Currie, P. (Chief Investigator (CI)), Ball, G. (Partner Investigator (PI)), Trapani, J. (Partner Investigator (PI)), Cadarso Busto, V. (Chief Investigator (CI)), Loessner, D. (Chief Investigator (CI)), Ecker, R. (Partner Investigator (PI)), Boyd, R. L. (Partner Investigator (PI)) & Lim, J. (Partner Investigator (PI))

    ARC - Australian Research Council, PolVax Pty Ltd, Cartherics Pty Ltd, TissueGUARD GmbH, Peter MacCallum Cancer Centre, TissueGnostics GmbH

    13/01/21 → 30/11/27

    Project: Research

Cite this